

Supplementary Information for

Reciprocal modulation of long noncoding RNA EMS and p53 regulates tumorigenesis

Chenfeng Wang^{1,#}, Yang Yang^{1,#}, Xianning Wu^{2,#}, Jingxin Li¹, Kaiyue Liu¹, Debao Fang¹, Bingyan Li¹, Ge Shan¹, Xinyu Mei^{2,*}, Fang Wang^{1,*} and Yide Mei^{1,2*}

*Correspondence: Yide Mei (Email: meiyide@ustc.edu.cn), Fang Wang (Email: wmfang@ustc.edu.cn), and Xinyu Mei (Email: mxyahslyy@163.com)

This PDF file includes:

Figs. S1 to S4 Tables S1

Supplementary Figures



Fig. S1. EMS down-regulates p53 expression. (A) H460 cells were infected with lentiviruses expressing control shRNA, EMS shRNA#1, or EMS shRNA#2. Forty-eight hours later, cell lysates and total RNA were analyzed by Western blotting and real-time RT-PCR, respectively. Data shown are mean \pm SD (n=3). **, p < 0.01; ***, p < 0.001; ns., no significance. (B) H460 cells were infected with lentiviruses expressing either control (pSin) or EMS (pSin-EMS). Forty-eight hours later, cell lysates and total RNA were analyzed by Western blotting and real-time RT-PCR, respectively. Data shown are mean \pm SD (n=3). *, p < 0.05; ns., no significance. (C and D) The intensities of the bands shown in Fig. 3E (C) and 3F (D) were quantified by using ImageJ software. The ratio of p53 to GAPDH is presented as bar graph. Data shown are mean \pm SD (n=3).



Fig. S2. The EMS-p53 axis regulates cellular senescence and cell proliferation. (A) Senescence-associated (SA) β -galactosidase staining in H460 cells expressing control shRNA, EMS shRNA#1, EMS shRNA#2, p53 shRNA, EMS shRNA#1 plus p53 shRNA, or EMS shRNA#2 plus p53 shRNA. The shown images are representative of three independent experiments. Data shown are mean \pm SD (n=3). *, p < 0.05; **, p < 0.01. (B) Shown are the growth curves of H460 cells expressing control shRNA, EMS shRNA#1, EMS shRNA#2, p53 shRNA, EMS shRNA#1 plus p53 shRNA, or EMS shRNA#2 plus p53 shRNA. Data shown are mean \pm SD (n=3). *, p <0.05; **, p < 0.01. (C) Colonies of H460 cells expressing control shRNA, EMS shRNA#1, EMS shRNA#2, p53 shRNA, EMS shRNA#1 plus p53 shRNA, or EMS shRNA#2 plus p53 shRNA were stained with crystal violet after 10 days of incubation. The shown images are representative of three independent experiments. Data shown are mean \pm SD (n=3). **, p < 0.01; ***, p < 0.001. (D) Western blot analysis of lysates from H460 cells expressing control shRNA, EMS shRNA#1, EMS shRNA#2, p53 shRNA, EMS shRNA#1 plus p53 shRNA, or EMS shRNA#2 plus p53 shRNA. (E) Senescence-associated (SA) β -galactosidase staining in H460 cells expressing control, EMS, p53, or both EMS and p53. The shown images are representative of three independent experiments. Data shown are mean \pm SD (n=3). **, p < 0.01; ns., no significance. (F) Shown are the growth curves of H460 cells expressing control, EMS, p53, or both EMS and p53. Data shown are mean \pm SD (n=3). *, p < 0.05; ns., no significance. (G) Colonies of H460 cells expressing control, EMS, p53, or both EMS and p53 were stained with crystal violet after 10 days of incubation. The shown images are representative of three independent experiments. Data shown are mean \pm SD (n=3). *, p < 0.05; ns., no significance. (H) Western blot analysis of lysates from H460 cells expressing control, EMS, p53, or both EMS and p53. (I) A549 cells were infected with lentiviruses expressing control, EMS shRNA, p53 shRNA, and E2F1 in the indicated combination. Forty-eight hours later, the cell growth curves were measured. Data shown are mean \pm SD (n=3). ***, p < 0.001. (J) Colonies of A549 cells expressing control, EMS shRNA, p53 shRNA, and E2F1 in the indicated combination were stained with crystal violet after 10 days of incubation. The shown images are representative of three independent experiments. Data shown are mean \pm SD (n=3). *, p < 0.05; **, p < 0.01. (K) Western blot analysis of lysates from A549 cells expressing control, EMS shRNA, p53 shRNA, and E2F1 in the indicated combination.



Fig. S3. EMS inhibits p53 expression through interaction with CPEB2. (A) Lysates from A549 cells were incubated with antisense biotin-labeled DNA oligomers against EMS, followed by the pull-down experiments using streptavidin-coated beads. The pull-downed proteins were eluted and analyzed by mass spectrometry. Listed are top 12 candidate binding proteins for EMS. (B) The input and immunoprecipitates from Fig. 5A were analyzed by Western blotting with anti-Flag antibody. (C) The efficient enrichment of endogenous EMS by its antisense DNA oligomers (Fig. 5B) was confirmed by real-time RT-PCR analysis. (D) A549 cells were infected with lentiviruses expressing control shRNA, EMS shRNA#1, or EMS shRNA#2. Forty-eight hours later, the poly(A) tail length of p53 mRNA was examined using the ligation-mediated poly(A) test (LM-PAT) assay. (E) A549 cells were infected with lentiviruses expressing control or EMS. Forty-eight hours later, the poly(A) tail length of p53 mRNA was examined using the ligation-mediated poly(A) test (LM-PAT) assay. (F) The intensities of the p53 bands in IP shown in Fig. 5H were quantified by using ImageJ software. Data shown are mean \pm SD (n=3). *, p < 0.05; **, p < 0.01; ns., no significance. (G) Shown is the psiCHECK2-based p53 3'-UTR reporter construct used for luciferase assay. (H) A549 cells expressing control shRNA, EMS shRNA#1, EMS shRNA#2, CPEB2 shRNA, EMS shRNA#1 plus CPEB2 shRNA, or EMS shRNA#2 plus CPEB2 shRNA were transfected with psi-

p53-3'UTR luciferase reporter plasmid. Twenty-four hours after transfection, the reporter activity was measured. Data shown are mean \pm SD (n=3). *, p < 0.05; ns., no significance. (I) The intensities of the p53 bands in IP shown in Fig. 5I were quantified by using ImageJ software. Data shown are mean \pm SD (n=3). ***, p < 0.001; ns., no significance. (J) A549 cells expressing EMS, Flag-CPEB2, or both Flag-CPEB2 and EMS were transfected with psi-p53-3'UTR luciferase reporter plasmid. Twenty-four hours after transfection, the reporter activity was measured. Data shown are mean \pm SD (n=3). *, p < 0.05; **, p < 0.01; ns., no significance. (K-M) A549 cells were infected with lentiviruses expressing control shRNA, EMS shRNA, CPEB2 shRNA, or both EMS shRNA and CPEB2 shRNA. Forty-eight hours later, polysomes in cytoplasmic extracts were fractionated by sucrose gradients (K). The levels of p53 (L) and GAPDH (M) mRNAs in each fraction were measured by real-time RT-PCR analysis and plotted as a percentage of the total p53 or GAPDH mRNA levels in that sample. NT, not translated; LMW, low-molecular-weight polysomes; HMW, high-molecular-weight polysomes. Data shown are mean \pm SD from three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001. (N) Shown are the sequences of poly(U) and putative CPE (cytoplasmic polyadenylation element) existing in EMS. EMS deletion mutants used in this study are also illustrated. (O) Purified recombinant Flag-CPEB2 bound with M2 beads was incubated with in vitro synthesized wild-type EMS, EMS- Δ CPE, EMS- Δ polyU, or EMS- Δ CPE- Δ polyU. The bead-bound RNAs were then eluted as templates for RT-PCR analysis. (P) A549 cells were infected with lentiviruses expressing wild-type EMS, EMS- Δ CPE, EMS- Δ polyU, or EMS- Δ CPE- Δ polyU. Forty-eight hours later, cell lysates were analyzed by Western blotting. (Q) A549 cells were infected with lentiviruses expressing wild-type EMS, EMS- Δ CPE, EMS- Δ polyU, or EMS- Δ CPE-ApolyU. Forty-eight hours later, total RNA was analyzed by real-time RT-PCR. Data shown are mean \pm SD (n=3). *, p < 0.05; **, p < 0.01; ns., no significance.



Fig. S4. Effects of EMS deletion mutants on cell proliferation and cellular transformation. (A) Shown are the growth curves of A549 cells expressing control, wild-type EMS, or EMS- Δ CPE- Δ polyU. Data shown are mean \pm SD (n=3). **, p < 0.01; ns., no significance. (B) Colonies of A549 cells expressing control, wild-type EMS, or EMS- Δ CPE- Δ polyU were stained with crystal violet after 10 days of incubation. The shown images are representative of three independent experiments. Data shown are mean \pm SD (n=3). **, p < 0.01; ns., no significance. (C and D) hTERTimmortalized BJ cells were sequentially infected with lentiviruses expressing EMS, EMS- Δ CPE-ApolyU, E7, and KRAS G12V in the indicated combination. (C) Forty-eight hours later, cell lysates were analyzed by Western blotting. (D) These cells were also subjected to soft agar colony formation assay. 20 days after seeding, colonies were stained with crystal violet and images were acquired. Numbers of colonies in six randomly selected areas ($40 \times$ magnification) were counted and averaged. Data shown are mean \pm SD (n=3). ***, p < 0.001; ns., no significance. (E and F) hTERT-immortalized BJ cells were sequentially infected with lentiviruses expressing EMS, CPEB2, E7, and KRAS G12V in the indicated combination. (E) Forty-eight hours later, cell lysates were analyzed by Western blotting. (F) These cells were also subjected to soft agar colony formation assay. 20 days after seeding, colonies were stained with crystal violet and images were acquired. Numbers of colonies in six randomly selected areas ($40 \times$ magnification) were counted and averaged. Data shown are mean \pm SD (n=3). **, p < 0.01; ns., no significance. (G) CPEB2 was expressed at relatively higher levels in lung adenocarcinoma (LUAD) with wild type p53 than in those carrying mutated p53.

Supplementary Table

β-Actin Fw:S'GACCTGACTGACTACCTCATGAAGAT3' Rev:S'GTCACACTTCATGATGAAGGT3' Rev:S'GTCACACTTCATGATGAAGGT3' GAPDH Fw:S'CCATGGGGAAGGTGAAGGTC3' Rev:S'GCAGTCATGATGAAGGCA3' Rev:S'GCCATCTACAAGCAGTCACAG3' P53 Fw:S'GCCATCTACAAGCAGTCACAGG3' Rew:S'TCATCCAAATACTCCACACGC3' Rew:S'GCGGTTTGGAGTGGTAGAA3' P21 Fw:S'TGTCACTGTCTTGTACCCTTG3' Rew:S'CACATCCTGTGTAAATGGAT3' Rew:S'CACATCCTGGTGTAAAATGCTTCTT3' CPEB2 Fw:S'ATGTCACTTGCCTGCAGTATTA3' Rev:S'CACATCCTGCTGCAGAATTGGGACGC3' EMS sense oligo DNA EMS sense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' EMS sense oligo DNA 5' (biotin-)GCGTCCCACTTCCTTGT3' Primers used for antisense oligomer affinity pul-down assays EMS sense oligo DNA CHIP-RE1 Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCCTCCTAAGTAGCTGGGATTA 3' CHIP-RE2 Fw: 5' GCCATCTGAGTCAGGAGTA 3' Rev: 5' TCCCGAGTAGCTGGGATTA 3' Rev: 5' TCCCGAGTAGCTGGGATTA 3' CHIP-RE4 Fw: 5' TCCCGAGTAGCTGGGATTA 3' Rev: 5' TCCCGAGTGGAGCAGAGAGGAGCGA3' Rev: 5' GCCATCTTGAGCTGTAGTC ' Rev: 5' TCCCGAGTGGAGCTGAGGTG' Rev: 5' GCCATCTTGAGCTGAGCAGGAGAGGAGAGGAGA'	Primers used in aRT-PCR assays		
Rev: 5'GTCACACTTCATGATGGAGTTGAAGG3' GAPDH Fw: 5'GCACGGGGAAGGTGAAGGTC3' Rev: 5'GAAGGGGTCATTGATGGCAAC3' P53 Fw: 5' GCCATCTACAAGCAGCAC3' P54 Fw: 5' TGTCACCATGTCTTGTACCCTG3' Rew: 5' TGTCACTGTCTTGTACCCTG3' Rew: 5' TGCCCGGAGAAATTGGAT3' EMS Fw: 5' TGTCACTGTCTTGTACCCTTG3' Rev: 5'GCGGTTTGGAGTGGTAAATTGCTTT3' CPEB2 Fw: 5' ATGTCACTGCTGCAGTATTA3' Rev: 5' GCGATCAGCACCTTCCTTTA 3' Primers used for antisense oligomer affinity pull-down assays EMS sense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' EMS sense oligo DNA 5' (biotin-)GCGTCCCACTTCCTTGCTTGT' Primers used in ChIP assays Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' CHIP-RE1 Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' TCCCGAGTAGCAGGAGTT 3' CHIP-RE2 Fw: 5' AGATCACGAGGTCAGGAGTT 3' Rev: 5' TCCCGAGTAGCTGGGTTTAT 3' Rev: 5' TCCCGAGTAGCAGGAGTCAGGAGT 3' GAPDH promoter Fw: 5' CGCACTCTTGAGCTGGGAGT 3' Rev: 5' TCCCGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	B-Actin	Fw:5'GACCTGACTGACTACCTCATGAAGAT3'	
GAPDH Fw: 5'CCATGGGGAAGGTGAAGGTC3' Rev: 5'GAAGGGGTCATTGATGGCAAC3' P53 Fw: 5' GCCATCTACAAGCAGTCACAG3' Rew: 5'TCATCCAAATACTCCACAGG3' Rew: 5'TCATCCAAATACTCCACAGG3' P21 Fw: 5'TGCACTGTCTTGTACCCTTG3' Rev: 5'GCGGTTTGGAATGGTAGAA3' EMS Fw: 5'TGCCACGGGAGAAATTGGAT3' Rev: 5'GCGATCAGCACCTTCTTA 3' Rev: 5'CCACATCCTGTGTAAATTGCTTCTT3' CPEB2 Fw: 5' ATGTCACTGCTGCAGTATA3' Primers used for antisense oligomer affinity pull-down assays EMS sense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' EMS antisense oligo DNA 5' (biotin-)GCGTCCCACTTCCTTGGTTT3' Primers used in ChIP assays Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' CHIP-RE1 Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' TGCCCACGCAGCACCTTT 3' Rev: 5' TGCCCTGCCTAATTTCGTATT 3' Rev: 5' TGCCCAGCAGGAGGAGAGT 3' CHIP-RE2 Fw: 5' CGAACAGGAGCTCAGGAGTT 3' Rev: 5' TCCCAGGTTTAGGCGGTTTA 3' Rev: 5' TCCCAGGTCAGGAGAGT 3' CHIP-RE4 Fw: 5' CGAACCAGGAGCAGAGAGAGGAGA' Rev: 5'TCGAACAGGAGAGAGAGAGAGAGAGA' shEMS#1 ShEMS#1 5'GATCACGAGCTAGAGCAGAGAGAGAGAGAGAA' s	F	Rev:5'GTCACACTTCATGATGGAGTTGAAGG3'	
Rev: 5'GAAGGGGTCATTGATGGCAAC3'P53Fw: 5' GCCATCTACAAGCAGTCACAG3'Rew: 5' GCCATCTACAAGCAGTCACAG3'Rew: 5' TCATCCAAATACTCCACACGC3'P21Fw: 5' TGTCACTGTCTTGTACCTTG3'Rew: 5'GGCGTTGGAGAGTGGTAGAA3'EMSFw: 5'GCGCGAGAAATTGGAT3'Rev: 5'CACATCCTGTGTAAATTGCTTCTT3'CPEB2Fw: 5' ATGTCACTGCCTGCAGTATTA3'Rev: 5' GCGATCAGCACCTTCCTTA 3'Primers used for antisense oligomer affinity pull-down assaysEMS sense oligo DNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS sense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'Rev: 5' TGCCCGGCTAATTCGTATT 3'CHIP-RE3Fw: 5' CGGAGCTTCAGGGGGATTA 3'CHIP-RE4Fw: 5' CGGAGCTTCCAGGCGGGAGCAGGAGCGG3'Rev: 5' TCCCGAGTAGCTGGGGTTAT 3'CHIP-RE4Fw: 5' GCCATCTTGAGCCGGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGAGTCAAGCAGAGAGCGAA3'shEMS#25'ACCTCGGCCATTCAGGTGAAC3'sh-control5'CCAAGGTTAAGCGACTCACACTAGGGAGAAGCGCGA'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) wasS'CCAAGCTTCAATACGACTCACTATAGGGAGA'	GAPDH	Fw: 5'CCATGGGGAAGGTGAAGGTC3'	
P53 Fw: 5' GCCATCTACAAGCAGTCACAG3' Rew: 5' TCATCCAAATACTCCACAGC3' P21 Fw: 5' TGTCACTGTCTTGACCCTTG3' Rev: 5'GGCGTTGGAGAGAAGA3' EMS Fw: 5'TGCCCGGGAGAAATTGGAT3' Rev: 5'CACATCCTGTGTAAATTGCTTCTT3' CPEB2 Fw: 5' ATGTCACTGCCTGCAGTATA3' Primers used for antisense oligomer affinity pull-down assays EMS sense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' EMS antisense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' Primers used for antisense oligomer affinity pull-down assays EMS EMS sense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' EMS antisense oligo DNA 5' (biotin-)GCGTCCCACTTCCTTGCTTT3' Primers used in ChIP assays EMS: 5' GCCTCCTAAGTAGCTGGGATTA 3' CHIP-RE1 Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' TGCCCGCGCTAATTTCGTAT 3' Rev: 5' TGCCCGGCTGCAGGAGCTAGGAGTT 3' CHIP-RE2 Fw: 5' CGCAGCTGCCAGGAGTTA 3' Rev: 5' TCCCAGGAGGTCAGGAGTTA 3' Rev: 5' TCCCAGGAGGTCAGGAGTTA 3' CHIP-RE4 Fw: 5' CGCAGCTTCAGGCCAGGCG3' Rev: 5' TCCCAGGGGGCG3' Rev: 5' TCCCAGGGGAGCAGAGAGAGAGGGA3' Oligonucleotide sequence of shRNAs shEMS#2 shEMS#2 5'ACTCTGGCCATTCAGGCAGAA3		Rev: 5'GAAGGGGTCATTGATGGCAAC3'	
Rew: 5' TCATCCAAATACTCCACACGC3'P21Fw: 5' TGTCACTGTCTTGTACCCTTG3'Rev: 5'GGCGTTTGGAGTGGTAGAA3'EMSFw: 5'TGCCCGGAGAAATTGGATGTTT3'CPEB2Fw: 5' ATGTCACTGTGTAAATTGCTTCTT3'Primers used for antisense oligomer affinity pull-down assaysEMS sense oligo DNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS antisense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used for antisense view of the transmission of transmission of the transmission of transmission	P53	Fw: 5' GCCATCTACAAGCAGTCACAG3'	
P21 Fw: 5' TGTCACTGTCTTGTACCCTTG3' Rev: 5'GGCGTTTGGAGTGGTAGAA3' EMS Fw: 5'TGCCCGGAGAAATTGGAT3' Rev: 5'CACATCCTGTGTAAATTGGTTCTT3' CPEB2 Fw: 5' ATGTCACTGCCTGCAGTATA3' Primers used for antisense oligomer affinity pull-down assays EMS sense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' EMS antisense oligo DNA 5' (biotin-)GCGTCCCACTTCCTTGCTTT3' Primers used in ChIP assays EMS CHIP-RE1 Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3' CHIP-RE2 Fw: 5' CGTCGTGATATCCAGGAGTTA 3' Rev: 5' TGCCCAGGTAGCTGGGGTTAT 3' Rev: 5' TCCCGAGTAGCTGGGGTTAT 3' CHIP-RE3 Fw: 5' AGATCACGAGGTCAGGAGTT 3' Rev: 5' TCCCGAGTAGCTGGGGTTAT 3' Rev: 5' TCCCGAGTAGCTGGGGTTAT 3' CHIP-RE4 Fw: 5' CGGAGCTTTCAGTCCAGTC 1' Rev: 5' TCCCAGCAGAGAGAGAGAGAGCGA3' Rev: 5' TCCGAACGAGGAGAGAGAGAGAGAGCGA3' Oligonucleotide sequence of shRNAs shEMS#1 shEMS#1 5'GACTCCAGTGGTAATCTAC3' sh-P53 5'GCTCAAGGTTCAGCCCTCG3' shEMS#2 5'ACCTCAGGTGAAACTGGGAA3' shEMS#1 5'CCAAGCTTCAGCATGAGCTGAACCAGA' <t< td=""><td></td><td>Rew: 5' TCATCCAAATACTCCACACGC3'</td></t<>		Rew: 5' TCATCCAAATACTCCACACGC3'	
Rev: 5'GGCGTTTGGAGTGGTAGAA3'EMSFw: 5'TGCGCGGAGAAATTGGAT3'Rev: 5'CACATCCTGTGTAAATTGCTTCTT3'CPEB2Fw: 5' ATGTCACTTGCCTGCAGTATTA3'Primers used for antisense oligomer affinity pull-down assaysEMS sense oligo DNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS sense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'Rev: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTTA 3'CHIP-RE4Fw: 5' CGATCATGAGCTGGGATTA 3'Rev: 5' TCCCGAGTAGCCGGGTTTAT 3'Rev: 5' TCCCGAGTAGCCGGGTTATA 3'CHIP-RE4Fw: 5' CGATCTTGAGCCGGATTA 3'Rev: 5' TCCCAAGTAGCCGGGCG3'Rev: 5' TCCGAACAGGAGAGAGAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAAA3'shEMS#25'ACTCTGGCCATTCAGGTGAACC3'sh-p535'GACTCCAGTGGTGAATCTAC3'sh-control5'CCTAAGGTTAAGTCAAGCCGCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCAATACGACTCACTCACACCATATAGGGAGA 3'	P21	Fw: 5' TGTCACTGTCTTGTACCCTTG3'	
EMS Fw: 5'TGCGCGGAGAAATTGGAT3' Rev: 5'CACATCCTGTGTAAATTGCTTCTT3' CPEB2 Fw: 5' ATGTCACTTGCCTGCAGTATTA3' Rev: 5' GCGATCAGCACCTTCCTTTA 3' Primers used for antisense oligomer affinity pull-down assays EMS sense oligo DNA 5' (biotin-)AAAGCAAGGAAGTGGGACGC3' EMS antisense oligo DNA 5' (biotin-)GCGTCCCACTTCCTTGCTTT3' Primers used in ChIP assays Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' CHIP-RE1 Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCGTAATCCCAGCACTTT 3' Rev: 5' TGCCCTGCCTAATTCGTATT 3' CHIP-RE2 Fw: 5' CGTCTGTAATCCCAGGAGTT 3' Rev: 5' TGCCCTGCCTAATTCGTATT 3' Rev: 5' TGCCGAGGTAGCTGGGGTTTAT 3' CHIP-RE3 Fw: 5' AGATCACGAGGTCAGGAGTT 3' Rev: 5' TCCCGAGTAGCTGGGGTTTAT 3' Rev: 5' TCCCGAGTAGCTGGGGTTTAT 3' CHIP-RE4 Fw: 5' CGAACATCTAGTCAGTC 3' GAPDH promoter Fw: 5'TACTAGCGGTTTACGGGCG3' Rev: 5'TCCGAACAGGAGAGAGAGAGAGCGA3' Oligonucleotide sequence of shRNAs shEMS#1 5'GATCACGAGTGAGTGAATCTAC3' sh-p53 5'GACTCCAGTGGTGAATCTAC3' sh-control 5'CCTAAGGTTAAGTCGCCCTCG3' Primers for in vitro transcription The 77 RNA polymerase sequence(T7) was 5'CCCAAGCTTC		Rev: 5'GGCGTTTGGAGTGGTAGAA3'	
Rev: 5'CACATCCTGTGTAAATTGCTTCTT3'CPEB2Fw: 5' ATGTCACTTGCCTGCAGTATTA3' Rev: 5' GCGATCAGCACCTTCCTTTA 3'Primers used for antisense oligomer affinity pull-down assaysEMS sense oligo DNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS antisense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGCAGAGARev: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' CCGACGGTTTACGTCAGTC 3'GAPDH promoterFw: 5'TCCGAACAGGAGGAGCAGAGAGCGGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGGAA3'shEMS#25'AGCTCCAGTGGTAATCTAC3'sh-p535'GACTCCAGTGGTAATTG3'sh-cOFEB25'AGCTTCAGCAGTAGATCAAGTGAACA'Sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCAAGCTCAATTAGGGAGA'	EMS	Fw: 5'TGCGCGGAGAAATTGGAT3'	
CPEB2Fw: 5' ATGTCACTTGCCTGCAGTATTA3' Rev: 5' GCGATCAGCACCTTCCTTTA 3'Primers used for antisense oligomer affinity pull-down assaysEMS sense oligo DNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS antisense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE3Fw: 5' CGTCTGTAATCCCAGCACTTT 3'CHIP-RE4Fw: 5' TGCCCTGCCTAAGTAGGAGTT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCAGGAGTT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCAGTC 'Rev: 5' TCCCGAAGTAGCTGGGGTTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' TCCGAACAGGAGGAGAGAGAGAGCGA3'GAPDH promoterFw: 5'TACTAGCGGTTTACGGGCG3'Rev: 5'TCCGAACAGGAGGAGCAGAGAGCGAA3'shEMS#15'GATAGACTAGATCAAGCAGAAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-cOFEB25'AGCTTCAGCAGTGAGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCAGCCCTCG3'Primers for in vitro transcriptionThe 77 RNA polymerase sequence(T7) was5'CCAAGCTTCAAGCTCACTACATCACATCACATCACATCA		Rev: 5'CACATCCTGTGTAAATTGCTTCTT3'	
Rev: 5' GCGATCAGCACCTTCCTTTA 3'Primers used for antisense oligo UNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS sense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCAGTC 'Rev: 5' CCGAGTAGCTGGGATTA 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' GCCATCTTGAGCCGGAGTC 3'GAPDH promoterFw: 5' CGGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNasshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAATCTAC3'sh-CPEB25'AGCTTCAAGTGAAGTGAAACTAG3'sh-control5'CCTAAGGTTAAGTCAAGTCAGTGAATTG3'Sh-control5'CCTAAGGTTAAGTCAAGTCAGATCAG3'The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATCCAACTCACTCACTCACTCACTCACTC	CPEB2	Fw: 5' ATGTCACTTGCCTGCAGTATTA3'	
Primers used for antisense oligo TAEMS sense oligo DNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS antisense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'Rev: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTT 3'Rev: 5' TCCCGAGTAGCTGGGATTA 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3'Rev: 5'TCCGAACAGGAGAGAGAGAGAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-cPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTCACATAGGGAGA 3'		Rev: 5' GCGATCAGCACCTTCCTTTA 3'	
EMS sense oligo DNA5' (biotin-)AAAGCAAGGAAGTGGGACGC3'EMS antisense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysFw: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'CHIP-RE3Fw: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE4Fw: 5' TCCCGAGTAGCTGGGATTA 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTACGGCG3'Rev: 5'TCCGAACAGGAGAGAGAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAAA3'shP.p535'GACTCCAGTGGTAATCTAC3'sh-P535'GACTCCAGTGGTAATCTAC3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTCACAGCAGAA3'	Primers used for antisense oligomer affinity pull-down assays		
EMS antisense oligo DNA5' (biotin-)GCGTCCCACTTCCTTGCTTT3'Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'CHIP-RE3Fw: 5' TGCCCTGCTAATTTCGTATT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCGGGTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' TCCGAACAGGAGCAGAGCGA3'GAPDH promoterFw: 5'TACTAGCGGTTTACGGGCG3'Rev: 5'TCCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'sheP535'GACTCCAGTGGTAATCTAC3'sh-cPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTCACTAAGGGAGA 3'	EMS sense oligo DNA	5' (biotin-)AAAGCAAGGAAGTGGGACGC3'	
Primers used in ChIP assaysCHIP-RE1Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'Rev: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTT 3'Rev: 5' TCCCGAGTAGCTGGGTTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTACGGCG3'Rev: 5'TCCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTCACGAGA3'	EMS antisense oligo DNA	5' (biotin-)GCGTCCCACTTCCTTGCTTT3'	
CHIP-RE1 Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3' Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3' CHIP-RE2 Fw: 5' CGTCTGTAATCCCAGCACTTT 3' Rev: 5' TGCCCTGCCTAATTTCGTATT 3' CHIP-RE3 Fw: 5' AGATCACGAGGTCAGGAGTT 3' Rev: 5' TCCCGAGTAGCTGGGTTTAT 3' CHIP-RE4 Fw: 5' CGGAGCTTTCAGTCCAGTC ' Rev: 5' GCCATCTTGAGCCTGTAGTC 3' GAPDH promoter Fw: 5'TACTAGCGGTTTTACGGGCG3' Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3' Oligonucleotide sequence of shRNAs shEMS#1 5'GATAGACTAGATCAAGCAGAA3' shEMS#2 5'ACTCTGGCCATTCAGGTGAAC3' sh-p53 5'GACTCCAGTGGTAATCTAC3' sh-control 5'CCTAAGGTTAAGTCGCCCTCG3' Primers for in vitro transcription The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTCAGGGAGA 3'	Primers used in ChIP assays		
Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3'Rev: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTT 3'Rev: 5' TCCCGAGTAGCTGGGTTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3'Rev: 5'TCGAACAGGAGGAGCAGAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-cPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAGGAGA3'	CHIP-RE1	Fw: 5' GCCTCCTAAGTAGCTGGGATTA 3'	
CHIP-RE2Fw: 5' CGTCTGTAATCCCAGCACTTT 3' Rev: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTT 3' Rev: 5' TCCCGAGTAGCTGGGTTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC ' Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3' Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAs shEMS#15'GATAGACTAGATCAAGCAGAA3'sh-p535'GACTCCAGTGGTAATCTAC3' sh-controlsh-control5'CCTAAGGTTAAGTCGACCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTCATAGGGAGA 3'		Rev: 5' GCCTCCTAAGTAGCTGGGATTA 3'	
Rev: 5' TGCCCTGCCTAATTTCGTATT 3'CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTT 3'Rev: 5' TCCCGAGTAGCTGGGTTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC 'Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3'Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-cOPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCTAATACGACTCACTCATAGGGAGA 3'	CHIP-RE2	Fw: 5' CGTCTGTAATCCCAGCACTTT 3'	
CHIP-RE3Fw: 5' AGATCACGAGGTCAGGAGTT 3' Rev: 5' TCCCGAGTAGCTGGGTTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC ' Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3' Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-cPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'		Rev: 5' TGCCCTGCCTAATTTCGTATT 3'	
Rev: 5' TCCCGAGTAGCTGGGTTTAT 3'CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC ' Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3' Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3' ShEMS#2shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3' Sh-controlsh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTAAGGGAGA 3'	CHIP-RE3	Fw: 5' AGATCACGAGGTCAGGAGTT 3'	
CHIP-RE4Fw: 5' CGGAGCTTTCAGTCCAGTC ' Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3' Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-cPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'		Rev: 5' TCCCGAGTAGCTGGGTTTAT 3'	
Rev: 5' GCCATCTTGAGCCTGTAGTC 3'GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3' Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3' ShEMS#2shEMS#25'ACTCTGGCCATTCAGGTGAAC3' S'GACTCCAGTGGTAATCTAC3'sh-p535'GACTCCAGTGGTAATCTAC3' Sh-controlsh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTACGAGAGA3'	CHIP-RE4	Fw: 5' CGGAGCTTTCAGTCCAGTC '	
GAPDH promoterFw: 5'TACTAGCGGTTTTACGGGCG3' Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-cPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'		Rev: 5' GCCATCTTGAGCCTGTAGTC 3'	
Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-CPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	GAPDH promoter	Fw: 5'TACTAGCGGTTTTACGGGCG3'	
Oligonucleotide sequence of shRNAsshEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-CPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'		Rev: 5'TCGAACAGGAGGAGCAGAGAGCGA3'	
shEMS#15'GATAGACTAGATCAAGCAGAA3'shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-CPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	Oligonucleotide sequence of shRNAs		
shEMS#25'ACTCTGGCCATTCAGGTGAAC3'sh-p535'GACTCCAGTGGTAATCTAC3'sh-CPEB25'AGCTTCAGCATGGTGATATTG3'sh-control5'CCTAAGGTTAAGTCGCCCTCG3'Primers for in vitro transcriptionThe T7 RNA polymerase sequence(T7) was5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	shEMS#1	5'GATAGACTAGATCAAGCAGAA3'	
sh-p53 5'GACTCCAGTGGTAATCTAC3' sh-CPEB2 5'AGCTTCAGCATGGTGATATTG3' sh-control 5'CCTAAGGTTAAGTCGCCCTCG3' Primers for in vitro transcription The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	shEMS#2	5'ACTCTGGCCATTCAGGTGAAC3'	
sh-CPEB2 5'AGCTTCAGCATGGTGATATTG3' sh-control 5'CCTAAGGTTAAGTCGCCCTCG3' Primers for in vitro transcription The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	sh-p53	5'GACTCCAGTGGTAATCTAC3'	
sh-control 5'CCTAAGGTTAAGTCGCCCTCG3' Primers for in vitro transcription The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	sh-CPEB2	5'AGCTTCAGCATGGTGATATTG3'	
Primers for in vitro transcription The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	sh-control	5'CCTAAGGTTAAGTCGCCCTCG3'	
The T7 RNA polymerase sequence(T7) was 5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	Primers for in vitro transcriptio	n	
5'CCAAGCTTCTAATACGACTCACTATAGGGAGA 3'	The T7 RNA polymerase sequence	e(T7) was	
	5'CCAAGCTTCTAATACGACTC	CACTATAGGGAGA 3'	
EMS(sense) 5' (T7)GTTTCCACCTAGGAC3'	EMS(sense)	5' (T7)GTTTCCACCTAGGAC3'	
5' TTTCATTTCACCTTTAATG3'		5' TTTCATTTCACCTTTAATG3'	
EMS(antisense) 5'GTTTCCACCTAGGACTACAG3'	EMS(antisense)	5'GTTTCCACCTAGGACTACAG3'	
5' (T7) TTTCATTTCACCTTTAATG3'		5' (T7) TTTCATTTCACCTTTAATG3'	
p53-3'UTR 5' (T7) CATTCTCCACTTCTTGTTCCC3'	p53-3'UTR	5' (T7) CATTCTCCACTTCTTGTTCCC3'	
5'GGCAGTGACCCGGAAGGC3'	*	5'GGCAGTGACCCGGAAGGC3'	
Primers for LM-PAT			
PAT-anchor-oligo d(T) 5'GCGAGCTCCGCGGCCGCGTTTTTTTTTTTT3'	PAT-anchor-oligo d(T)	5'GCGAGCTCCGCGGCCGCGTTTTTTTTTTTT3'	

Table S1. Oligonucleotides used in this study

PAT-p53-specific oligomers	5'CTGCATTTTCACCCCACCCTTCC3'
Primers for RT-PCR assays	
p53-3'UTR	Fw: 5'GGAGTAGGACATACCAGCTTAGA3'
	Rew: 5'CCTACCTAGAATGTGGCTGATTG3'
EMS and its antisense RNA	Fw: 5'TGCGCGGAGAAATTGGAT3'
	Rev: 5'CACATCCTGTGTAAATTGCTTCTT3'